Spartalizumab Explained

Type:	mab
Mab Type:	mab
Source:	zu
Target:	PD-1 (CD279)
Cas Number:	1935694-88-4
Unii:	QOG25L6Z8Z
Atc Prefix:	none
Kegg:	D11605
Synonyms:	PDR001

Spartalizumab (INN;^[1] development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma.

This drug is being developed by Novartis., spartalizumab is undergoing Phase III trials.^[2]

References

1. . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117 . WHO Drug Information . 31 . 2 . 2017 .
2. Kaplon H, Muralidharan M, Schneider Z, Reichert JM . Antibodies to watch in 2020 . mAbs . 12 . 1 . 1703531 . 2020 . 31847708 . 6973335 . 10.1080/19420862.2019.1703531 .